Managing pregnancy-associated clinical emergencies in systemic lupus erythematosus: a case-based approach

References

• Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing disease activity in SLE patients during pregnancy. Lupus. 1999;8(8):677–684.
   PubMed Web of Science ®Google Scholar
• Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcome in a prospective, multiethnic cohort of lupus patients. Ann Intern Med. 2015;163(3):153.
   PubMed Web of Science ®Google Scholar
• Butalia S, Audibert F, Côté A-M, et al. Hypertension Canada’s 2018 guidelines for the management of hypertension in pregnancy. Can J Cardiol. 2018;34(5):526–531.
   PubMed Web of Science ®Google Scholar
• Gupta M, Feinberg BB, Burwick RM. Thrombotic microangiopathies of pregnancy: differential diagnosis. Pregnancy Hypertens. 2018;12:29–34.
   PubMed Web of Science ®Google Scholar
• Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Hematol Oncol Clin North Am. 2017;31(6):1081–1103.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169(4):1000–1006.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Brewer JM, Wallace K, et al. HELLP syndrome and composite major maternal morbidity: importance of Mississippi classification system. J Matern Fetal Neonatal Med. 2013;26(12):1201–1206.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006;195(4):914–934.
   PubMed Web of Science ®Google Scholar
• Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstetrics Gynecol. 2004;103(5):981–991.
   PubMed Web of Science ®Google Scholar
• Magee LA, von Dadelszen P, Singer J, et al. The CHIPS randomized controlled trial (control of hypertension in pregnancy study) is severe hypertension just an elevated blood pressure? Hypertension. 2016;68(5):1153–1159.
   PubMed Web of Science ®Google Scholar
• Woudstra DM, Chandra S, Hofmeyr GJ, et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev. 2010;9. DOI:10.1002/14651858.CD008148.pub2.
   Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
   PubMed Web of Science ®Google Scholar
• Schummers L, Hutcheon JA, Hernandez-Diaz S, et al. Association of short interpregnancy interval with pregnancy outcomes according to maternal age. JAMA Intern Med. 2018;178(12):1661–1670.
   PubMed Web of Science ®Google Scholar
• Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol. 1982;142(2):159–167.
   PubMed Web of Science ®Google Scholar
• Kınay T, Kayıkçıoğlu F, Küçük C, et al. Severe preeclampsia versus HELLP syndrome: maternal and perinatal outcomes at. Balkan Med J. 2015;32(4):359–363.
   PubMed Web of Science ®Google Scholar
• Dusse LM, Alpoim PN, Silva JT, et al. Revisiting HELLP syndrome. Clin Chim Acta. 2015;451:117–120.
   PubMed Web of Science ®Google Scholar
• Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007;196(2):147.
   PubMedGoogle Scholar
• Audibert F, Friedman SA, Frangieh AY, et al. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol. 1996;175(2):460–464.
   PubMed Web of Science ®Google Scholar
• Vaught AJ, Braunstein EM, Jagar Jasem XY, et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018;3:6.
   Web of Science ®Google Scholar
• Chan W-S, Rey E, Kent NE, et al. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecology Canada. 2014;36(6):527–553.
   PubMedGoogle Scholar
• Vaught AJ, Gavriilaki E, Hueppchen N, et al. Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. Exp Hematol. 2016;44(5):390–398.
   PubMed Web of Science ®Google Scholar
• Burwick R, Feinberg B. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34(2):201–203.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Jamison M, Myers E, et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199(2):127. e1–e6.
   PubMed Web of Science ®Google Scholar
• Bundhun PK, Soogund MZS, Huang F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001–2016. J Autoimmun. 2017;79:17–27.
   PubMed Web of Science ®Google Scholar
• Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060–2068.
   PubMed Web of Science ®Google Scholar
• Burgner A, Hladunewich MA. Women’s reproductive health for the nephrologist. Am J Kidney Dis. 2019;74(5):675–681.
   PubMed Web of Science ®Google Scholar
• Jakobsen IM, Helmig RB, Stengaard-Pedersen K, et al. Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990–2010. Scand J Rheumatol. 2015;44(5):377–384.
   PubMed Web of Science ®Google Scholar
• Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood. 2014;123(3):404–413.
   PubMed Web of Science ®Google Scholar
• Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–485.
   PubMed Web of Science ®Google Scholar
• Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010–2021.
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017;31(6):406–417.
   PubMed Web of Science ®Google Scholar
• Manukyan D, Muller-Calleja N, Jackel S, et al. Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice. J Thromb Haemost. 2016;14(5):1011–1020.
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, Brodsky RA, McCrae KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol. 2019;10:449.
   PubMed Web of Science ®Google Scholar
• Redecha P, Franzke C-W, Ruf W, et al. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest. 2008;118(10):3453–3461.
   PubMed Web of Science ®Google Scholar
• Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177(7):4794–4802.
   PubMed Web of Science ®Google Scholar
• Riedl M, Noone DG, Khan MA, et al. Complement activation induces neutrophil adhesion and neutrophil-platelet aggregate formation on vascular endothelial cells. Kidney Int Rep. 2017;2(1):66–75.
   PubMed Web of Science ®Google Scholar
• Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features. Autoimmun Rev. 2015;14(5):401–414.
   PubMed Web of Science ®Google Scholar
• Bertolaccini M, Amengual O, Atsumi T, et al. ‘Non-criteria’aPL tests: report of a task force and preconference workshop at the 13th international congress on antiphospholipid antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20(2):191–205.
   PubMed Web of Science ®Google Scholar
• Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, et al. Closing the serological gap in the antiphospholipid syndrome: the value of “non-criteria” antiphospholipid antibodies. J Rheumatol. 2017;44(11):1597–1602.
   PubMed Web of Science ®Google Scholar
• Legault K, Schunemann H, Hillis C, et al. McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018;16(8):1656–1664.
   Web of Science ®Google Scholar
• Unlu O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3(2):75–84.
   PubMed Web of Science ®Google Scholar
• Franco J-S, Molano-González N, Rodríguez-Jiménez M, et al. The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. PloS One. 2014;9(10):e110242.
   PubMed Web of Science ®Google Scholar
• McMahon M, Keogan M, O’Connell P, et al. The prevalence of antiphospholipid antibody syndrome among systemic lupus erythematosus patients. Ir Med J. 2006;99(10):296–298.
   PubMedGoogle Scholar
• Chen J, Sun S, Yan Q, et al. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study. Clin Rheumatol. 2016;35(2):333–340.
   PubMed Web of Science ®Google Scholar
• Mustonen P, Lehtonen KV, Javela K, et al. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus. 2014;23(14):1468–1476.
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Andreoli L, Scanzi F, et al. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10–20.
   PubMed Web of Science ®Google Scholar
• Gotestam Skorpen C, Lydersen S, Gilboe IM, et al. Women with systemic lupus erythematosus get pregnant more easily than women with rheumatoid arthritis. Rheumatology. 2018;57(6):1072–1079.
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–1832.
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93(06):1147–1152.
   PubMedGoogle Scholar
• Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237–242.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Sanna G, Murru V, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354–364.
   PubMed Web of Science ®Google Scholar
• Shi H, Zheng H, Yin Y-F, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56:614.
   PubMed Web of Science ®Google Scholar
• De Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7(11):1767–1773.
   PubMed Web of Science ®Google Scholar
• de Laat B, Derksen RH, Urbanus RT, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2–glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105(4):1540–1545.
   PubMed Web of Science ®Google Scholar
• Abou-Nassar K, Carrier M, Ramsay T, et al. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011;128(1):77–85.
   PubMed Web of Science ®Google Scholar
• Faden D, Tincani A, Tanzi P, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-β2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstetrics Gynecol Reprod Biol. 1997;73(1):37–42.
   PubMed Web of Science ®Google Scholar
• Katano K, Aoki K, Sasa H, et al. β2-glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod. 1996;11(3):509–512.
   PubMed Web of Science ®Google Scholar
• Yelnik CM, Laskin CA, Porter TF, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016;3(1):e000131.
   PubMed Web of Science ®Google Scholar
• Skeith L, Abou-Nassar KE, Walker M, et al. Are Anti-β2 glycoprotein 1 antibodies associated with placenta-mediated pregnancy complications? A nested case–control study. Am J Perinatol. 2018;35(11):1093–1099.
   PubMed Web of Science ®Google Scholar
• Marchetti T, De Moerloose P, Gris J. Antiphospholipid antibodies and the risk of severe and non‐severe pre‐eclampsia: the NOHA case‐control study. J Thromb Haemost. 2016;14(4):675–684.
   PubMed Web of Science ®Google Scholar
• Silver RM, Parker CB, Reddy UM, et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol. 2013;122(3):641.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Radin M, Sanna G, et al. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatology. 2018;57(4):661–665.
   PubMed Web of Science ®Google Scholar
• Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheumatism. 2012;64(2):504–512.
   PubMedGoogle Scholar
• Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296–1304.
   Google Scholar
• Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584–1589.
   PubMed Web of Science ®Google Scholar
• Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Bmj. 1997;314(7076):253–257.
   PubMed Web of Science ®Google Scholar
• Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100(3):408–413.
   PubMed Web of Science ®Google Scholar
• Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit. 2006;12(3):Cr132–6.
   PubMed Web of Science ®Google Scholar
• Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol. 2009;36(2):279–287.
   PubMed Web of Science ®Google Scholar
• van Hoorn ME, Hague WM, van Pampus MG, et al. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol. 2016;197:168–173.
   PubMed Web of Science ®Google Scholar
• Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S–e736S.
   PubMed Web of Science ®Google Scholar
• New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ = Journal De l’Association Medicale Canadienne. 2003;169(3):207–208.
   Google Scholar
• van der Heijde D, Aletaha D, Carmona L, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74(1):8–13.
   PubMed Web of Science ®Google Scholar
• Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Cmaj. 2010;182(18):E839–E42.
   PubMed Web of Science ®Google Scholar
• Bala MM, Paszek E, Lesniak W, et al. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev. 2018;7. DOI:10.1002/14651858.CD012534.pub2.
   PubMedGoogle Scholar
• Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
   PubMed Web of Science ®Google Scholar
• Cairoli E, Rebella M, Danese N, et al. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21(11):1178–1182.
   PubMed Web of Science ®Google Scholar
• Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013;40(1):30–33.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Cuadrado M, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–218.
   PubMed Web of Science ®Google Scholar
• Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to improve pregnancy outcome in women with anTIphospholipid antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost. 2017;43(6):562–571.
   PubMed Web of Science ®Google Scholar
• Skeith L. Preventing venous thromboembolism during pregnancy and postpartum: crossing the threshold. Hematol Am Soc Hematol Educ Program. 2017;2017(1):160–167.
   PubMedGoogle Scholar
• Hossain N, Paidas MJ. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin Perinatol. 2007;31(4):208–212.
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheumatism. 2012;64(7):2311–2318.
   PubMed Web of Science ®Google Scholar
• Saccone G, Berghella V, Maruotti GM, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216(5):525.e1-.e12.
   Web of Science ®Google Scholar
• Kim MY, Guerra MM, Kaplowitz E, et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018;77(4):549–555.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–291.
   PubMed Web of Science ®Google Scholar
• Yuen SY, Krizova A, Ouimet JM, et al. Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: results from a case control study and literature review. Open Rheumatol J. 2008;2:89.
   PubMedGoogle Scholar
• Magid MS, Kaplan C, Sammaritano LR, et al. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol. 1998;179(1):226–234.
   PubMed Web of Science ®Google Scholar
• Klumb EM, Barros L, Romeiro L, et al. The impact of nephritis on gestational results in women with systemic lupus erythematosus. Rev Bras Reumatol Engl Ed. 2005;45(3):107–113.
   Google Scholar
• Bell WR, Braine HG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med. 1991;325(6):398–403.
   PubMed Web of Science ®Google Scholar
• Hamasaki K, Mimura T, Kanda H, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol. 2003;22(4–5):355–358.
   PubMed Web of Science ®Google Scholar
• Ghosh G, Grewal J, Männistö T, et al. Racial/ethnic differences in pregnancy-related hypertensive disease in nulliparous women. Ethn Dis. 2014;24(3):283.
   PubMed Web of Science ®Google Scholar
• Saavedra MA, Cruz-Reyes C, Vera-Lastra O, et al. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. Clin Rheumatol. 2012;31(5):813–819.
   PubMed Web of Science ®Google Scholar
• Baron J, Baron B. Thrombotic thrombocytopenic purpura and its look-alikes. Clin Adv Hematol Oncol. 2005;3(11):868–874.
   PubMedGoogle Scholar
• Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–2846.
   PubMed Web of Science ®Google Scholar
• George JN. How I treat patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Blood. 2000;96(4):1223–1229.
   PubMed Web of Science ®Google Scholar
• Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology. 2011;50(5):824–829.
   PubMed Web of Science ®Google Scholar
• George JN, Chen Q, Deford CC, et al. Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency. J Clin Apher. 2012;27(6):302–311.
   PubMed Web of Science ®Google Scholar
• Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262–1267.
   PubMed Web of Science ®Google Scholar
• Szymanik-Grzelak H, Przychodzen J, Stelmaszczyk-Emmel A, et al. Thrombotic thrombocytopenic purpura in the course of systemic lupus erythematosus in a 15-year-old girl. Cent Eur J Immunol. 2017;42(4):407–408.
   PubMed Web of Science ®Google Scholar
• Matsuyama T, Kuwana M, Matsumoto M, et al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost. 2009;101(02):371–378.
   Google Scholar
• Mannucci PM, Vanoli M, Forza I, et al. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica. 2003;88(8):914–918.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98(9):2730–2735.
   PubMed Web of Science ®Google Scholar
• Stirling Y, Woolf L, North W, et al. Haemostasis in normal pregnancy. Thromb Haemost. 1984;51(02):176–182.
   Google Scholar
• Reese JA, Muthurajah DS, Hovinga JAK, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013;60(10):1676–1682.
   PubMed Web of Science ®Google Scholar
• Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142(5):819–826.
   PubMed Web of Science ®Google Scholar
• George JN. The association of pregnancy with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Curr Opin Hematol. 2003;10(5):339–344.
   PubMed Web of Science ®Google Scholar
• Vesely SK, Li X, McMinn J, et al. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Transfusion. 2004;44(8):1149–1158.
   PubMed Web of Science ®Google Scholar
• Vaidya S, Abul-ezz S, Lipsmeyer E. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Scand J Rheumatol. 2001;30(5):308–310.
   PubMed Web of Science ®Google Scholar
• Jiang H, An X, Li Y, et al. Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011. Clin Rheumatol. 2014;33(3):419–427.
   PubMed Web of Science ®Google Scholar
• Delgado-Garcia G, Camara-Lemarroy C, Infante-Valenzuela A, et al. Pure lupus podocytopathy first presenting as thrombotic thrombocytopenic purpura-like syndrome. Clin Rheumatol. 2016;35(8):2131–2136.
   PubMed Web of Science ®Google Scholar
• El Khayat SS, Medkouri G, Etomba AM, et al. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus: a rare and life-threatening association. Arab J Nephrol Transplant. 2012;5(2):103–105.
   PubMedGoogle Scholar
• Roriz M, Landais M, Desprez J, et al. Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura. Medicine (Baltimore). 2015;94(42):e1598.
   PubMed Web of Science ®Google Scholar
• Georgiades F, Demosthenous S, Braimi M, et al. Takotsubo cardiomyopathy and thrombotic thrombocytopenic purpura preceding a lupus diagnosis: a case report. Lupus. 2015;24(13):1443–1447.
   PubMed Web of Science ®Google Scholar
• Grzegowska D, Masiak A, Czuszynska Z, et al. Thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus–complication of connective tissue disease or overlap syndrome?. Pomeranian J Life Sci. 2015;61(2):167–172.
   PubMedGoogle Scholar
• Prasun Giri P, Sinha R, Pal P, et al. Therapeutic plasma exchange in paediatric SLE: a case series from India. Lupus. 2015;24(8):889–891.
   PubMed Web of Science ®Google Scholar
• Abu-Hishmeh M, Sattar A, Zarlasht F, et al. Systemic lupus erythematosus presenting as refractory thrombotic thrombocytopenic purpura: a diagnostic and management challenge. A case report and concise review of the literature. Am J Case Rep. 2016;17:782–787.
   PubMed Web of Science ®Google Scholar
• Merayo-Chalico J, Demichelis-Gomez R, Rajme-Lopez S, et al. Risk factors and clinical profile of thrombotic thrombocytopenic purpura in systemic lupus erythematosus patients. Is this a distinctive clinical entity in the thrombotic microangiopathy spectrum?: A case control study. Thromb Res. 2014;134(5):1020–1027.
   PubMed Web of Science ®Google Scholar
• Palaniappan P, Lionel AP, Agarwal I, et al. Cryosupernatant and Immunosuppression as effective alternative therapies for TTP in three pediatric SLE patients. Indian J Hematol Blood Transfus. 2014;30(Suppl 1):232–236.
   PubMedGoogle Scholar
• Wang Y, Zhang JY, Niu ZY, et al. Clinical analysis of 14 patients with thrombotic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye xue Za Zhi. 2014;22(2):407–411.
   PubMedGoogle Scholar
• Changcharoen B, Bolger DT Jr. Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody. BMJ Case Rep. 2015;2015:bcr2014208477.
   PubMedGoogle Scholar
• Pan YX, Wang HY, Shang YT, et al. Clinical analysis of 12 cases of systemic lupus erythematosus associated with thrombotic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye xue Za Zhi. 2017;25(4):1147–1150.
   PubMedGoogle Scholar
• John ML, Scharrer I. Autoimmune disorders in patients with idiopathic thrombotic thrombocytopenic purpura. Hamostaseologie. 2012;32(Suppl 1):S86–9.
   PubMedGoogle Scholar
• Kafle P, Malakoff GL. Coexistence of systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report. Tenn Med. 2012;105(5):37–38.
   PubMedGoogle Scholar
• Cui J, Zhu TN, Zhao YQ, et al. The clinical analysis of 14 cases of systemic lupus erythematosus complicated by thrombotic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi. 2013;52(5):383–386.
   PubMedGoogle Scholar
• Garcia Boyero R, Mas Esteve E, Mas Esteve M, et al. Systemic lupus erythematosus and thrombotic thrombocytopenia purpura: a refractory case without lupus activity. Reumatol Clin. 2013;9(6):373–375.
   PubMedGoogle Scholar
• Umibe T, Nawata Y, Mori N, et al. Thrombotic thrombocytopenic purpura (TTP) observed in a patient with primary antiphospholipid antibody syndrome. Ryumachi [Rheumatism]. 1994;34(6):981–987.
   PubMedGoogle Scholar
• Cao L, Morro M, Lally T, et al. Surge of anti-SS-A antibody associated with fulminant thrombotic thrombocytopenic purpura in pregnancy. South Med J. 2001;94(12):1219–1222.
   PubMed Web of Science ®Google Scholar
• Vasoo S, Thumboo J, Fong KY. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus. 2002;11(7):443–450.
   PubMed Web of Science ®Google Scholar
• Jiang Y, McIntosh JJ, Reese JA, et al. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014;123(11):1674–1680.
   PubMed Web of Science ®Google Scholar
• Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998;28(1):1–19.
   PubMed Web of Science ®Google Scholar
• Letchumanan P, Ng HJ, Lee LH, et al. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology. 2009;48(4):399–403.
   PubMed Web of Science ®Google Scholar
• Abou-Nassar K, Karsh J, Giulivi A, et al. Successful prevention of thrombotic thrombocytopenic purpura (TTP) relapse using monthly prophylactic plasma exchanges throughout pregnancy in a patient with systemic lupus erythematosus and a prior history of refractory TTP and recurrent fetal loss. Transfus Apher Sci. 2010;43(1):29–31.
   PubMed Web of Science ®Google Scholar
• Friedrichs B, Tiemann M, Salwender H, et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica. 2006;91(10):1426–1427.
   PubMed Web of Science ®Google Scholar
• Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–1506.
   PubMed Web of Science ®Google Scholar
• De Cock D, Birmingham L, Watson KD, et al. Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. Rheumatology. 2017;56(4):661–663.
   PubMed Web of Science ®Google Scholar
• Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453.
   PubMed Web of Science ®Google Scholar
• Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–1859.
   PubMed Web of Science ®Google Scholar
• El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2015;65(1):127–130.
   PubMed Web of Science ®Google Scholar
• Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wu H, Khosravi M, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011;7(5):e1002079.
   PubMed Web of Science ®Google Scholar